Subscribe to Search results

Dr Mayne cited a paper by J Spero that structural abnormalities of the liver were described in patients. The paper discusses a study on haemophiliacs deficient in factor VIII or IX where significant numbers showed signs of chronic liver disease.

Published on:

A report by Dr Preston that revealed 77 percent of haemophiliac patients following a systematic screening in Sheffield were revealed to have abnormal liver-function.

Published on:

Dr Preston told the Lindsay Tribunal in 1978 that there was a broad spectrum of chronic liver disease which was both concerning and surprising.

Published on:

After reading the 1978 Sheffield/Preston paper, Dr Colvin accepted that clinicians could no longer work on the assumption that the absence of overt or acute signs was a reliable indicator that a person would not develop NANBH.

Published on:

In Edinburgh the principal product used in 1976 was cryoprecipitate.

Published on:

In Edinburgh the principal product used in 1977 was cryoprecipitate.

Published on:

In Edinburgh the principal product used in 1978 was cryoprecipitate.

Published on:

In Edinburgh the principal product used in 1979 was cryoprecipitate.

Published on:

From 1980, when Professor Ludlam arrived in Edinburgh, the volume of NHS concentrates used exceeded the volume of cryoprecipitate for the first time.

Published on:

In 1974 - 1975, at the Glasgow Royal Infirmary while commercial concentrates were in use cryoprecipitate was the predominant product.

Published on:

During the 1980, the haemophilia centre at the Royal Hospital for Sick Children ("RHSC") in Yorkhill, Glasgow, provided haemophilia treatment to children from the Glasgow area and across the West of Scotland. 55 had Haemophilia A, 14 had Haemophilia B and 1 had von Willebrand disease.

Published on:

The annual return taken from Glasgow in 1976, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1977, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1978, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1979 saw a reduction in the use of cryoprecipitate and an increase in the use of concentrates, both NHS and (in particular) commercial

Published on:

Evidence presented to the Penrose Inquiry by Dr Forbes stated that the majority of discussions taking place around 1975 were centred around the types of donors used to give plasma in commercial centres.

Published on:

Evidence presented to the Penrose Inquiry by Dr Forbes held that the risk of dying due to a bleed outweighed the possible downside of using factor concentrates.

Published on:

Dr Forbes agrees with a letter written by Dr John Cash on 24 January 1976, with held that that the importation of Factor VIII concentrates was "bringing with it a potentially lethal virus into the whole community" in reference to hepatitis.

Published on:

During 1978, before the complications had become apparent, Dr Forbes described the recent move to home treatment as highly valuable for patients.

Published on:

By 1976 Factor 9 concentrate was the dominant treatment with comparatively little use of fresh frozen plasma. The 1976 annual returns recorded that 396 patients were treated with a total of 5,561,834 Factor 9 units in the UK. The average per patient was 18,790 units. 60 patients were on home treatment.

Published on: